Table 6.
Association between the adjuvant therapy and TM-LVI status was assessed in each clinical stage.
| Location | TNM stage | TM-LVI | P | ||
|---|---|---|---|---|---|
| A Number (%) | B Number (%) | C Number (%) | |||
| Colon | I | 35(2.1%) | 5(2.0%) | 4(8.5%) | 0.013 |
| IIa | 148(11.3%) | 85(14.1%) | 44(18.5%) | 0.0054 | |
| IIb | 44(23.4%) | 33(21.3%) | 17(19.8%) | 0.77 | |
| IIc | 15(19.5%) | 14(21.2%) | 11(22.9%) | 0.90 | |
| IIIa | 145(67.1%) | 46(62.2%) | 5(31.3%) | 0.014 | |
| IIIb | 398(61.1%) | 401(66.7%) | 261(62.3%) | 0.10 | |
| IIIc | 58(80.6%) | 112(70.9%) | 130(63.4%) | 0.0003 | |
| Rectum | I | 45(3.9%) | 14(6.3%) | 2(4.0%) | 0.25 |
| IIa | 86(14.8%) | 85(19.4%) | 37(21.1%) | 0.059 | |
| IIb | 12(20.7%) | 26(34.2%) | 11(22.5%) | 0.16 | |
| IIc | 9(26.5%) | 8(26.7%) | 13(44.8%) | 0.22 | |
| IIIa | 151(77.8%) | 72(73.5%) | 11(52.4%) | 0.036 | |
| IIIb | 272(73.5%) | 293(72.7%) | 225(68.8%) | 0.34 | |
| IIIc | 34(66.7%) | 68(75.6%) | 117(75.0%) | 0.45 | |
The application of adjuvant therapy was not related to the risk of recurrence as estimated by TM-LVI status except for stage IIa CC. Red circles indicated that TM-LVI was an independent prognostic factor for both relapse-free survival and disease specific survival. Adjuvant therapy may be recommended according to TM-LVI status in these stages.
Bold type, P < 0.05.